Join Our Penny Stock Newsletter

Arno Therapeutics, Inc. - ARNI

RSI %R Tweets Wolf Odds
53 -96 0 31.205%

Industry: Biotechnology / Sector: Healthcare

ARNI Chart

ARNI Quote

Prev Close: 0.003
Open: 0.0030
Last Trade: 0.0025
Change %: -16.670%
Change: -0.0005000
Volume: 248610
Avg Vol: 209270
Relative Vol: 1.19
Day Range: 0.0025 -0.003
52-Week Range: 0.0100 - 0.4000
Market Cap: 1.98M
Float: 15.03M
Shares Outstanding: 49.35M
Insider Owned: 41.01%
Institution Owned: 34.89%
Beta: 1.66
PE Ratio: 0.00
EPS: -0.3770

ARNI Detailed Stats

RSI:53.13 %K:4.44 Wolf Odds: 31.205% Tweets Today:0 SMA14:0.0054
stochRSI:0.13 %D:8.35 Wolf Trend:0.07 Tweet Avg:15 Pivot Price:0.0026667
%R:-95.56 %B:0.26 Wolf 3-Day:0.07 Avg. Change 3-Day:+0.977% Resistance 1:0.0028333
MFI:42.52 Bandwidth:2.503311 Wolf 7-Day:0.05 Avg. Change 7-Day:-10.826% Resistance 2:0.0031667
WolfPeak:0.05 Vortex Indicator:0.01 Wolf 14-Day:0.13 Avg. Change 14-Day:+56.12% Support 1:0.0023333
ROC 7/14:-64.2857/66.6667 Aroon Oscillator:21.4286 EOM:0.000398 Relative Vol:1.19 Support 2:0.0021667
RSI Alert:None WolfPeak Alert:None Vortex Alert:Potential Bear Aroon Alert:None EOM Alert:None

Featured News *

ARNI News

    ARNI Description

    Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company?s product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. Its product development pipeline also consists of AR-12, an orally available cancer treatment, which has completed Phase I clinical study for the treatment of solid tumors and hematological malignancies, as well as in Pre-clinical studies for the treatment of various anti-microbial targets. In addition, the company?s product development pipeline comprises AR-42, a novel orally available cancer therapy that is in Phase I investigator-initiated clinical study for the treatment of hematological malignancies and solid tumors. The company has license agreements with Invivis Pharmaceuticals, Inc.; the Regents of the University of Minnesota; and the Ohio State University Innovation Foundation, as well as a co-development agreement with Leica Biosystems Newcastle Ltd. Arno Therapeutics, Inc. is based in Flemington, New Jersey.
    Website: http://www.arnothera.com

    ARNI Comments

    Recent ARNI Tweets

    Powered by Ekonomys ver. 9

    StockWolf is dedicated to Penny Stock quotes and data to provide information, news, and education on penny stocks to help in your due diligence.

    30min+ delay on data. All data is picked with automated algorithms and not vetted for accuracy. Please, read ALL information and disclaimers before using our service. StockWolf is not a licensed financial adviser, and not liable for your loses. Trade responsibly. This site is for education purposes only not a recommendation to buy/sell

    Information

    Stock Wolf Twitter

    Stock Wolf Facebook